drugset / Trial / NCT04501744
A Study of M701 (EpCAM and CD3) in Malignant Ascites
NaSingle-groupOpen-labelTreatment
Summary
This study is to investigate the safety, tolerability, PK, PD and immunogenicity of multiple ascending doses of M701 administered intraperitoneally to patients with malignant ascites caused by advanced solid tumors.
Timeline
- Start
- 2018-09-30
- Primary completion
- 2022-02-28
- Completion
- 2022-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | M701 | Monoclonal antibody | 25 ug | Other |
| Subject | M701 | Monoclonal antibody | 50 ug | Other |
| Subject | M701 | Monoclonal antibody | 100 ug | Other |
| Subject | M701 | Monoclonal antibody | 200 ug | Other |
| Subject | M701 | Monoclonal antibody | 300 ug | Other |
| Subject | M701 | Monoclonal antibody | 400 ug | Other |
| Subject | M701 | Monoclonal antibody | 500 ug | Other |